SCLX: An Innovative and Growing Pain Management Company
NASDAQ:SCLX
READ THE FULL SCLX RESEARCH REPORT
Scilex Holding Company (NASDAQ:SCLX) is a revenue-generating company that is focused on addressing one of the biggest issues facing humanity today—that of the overuse of opioids. Scilex is focused on developing non-opioid pain management products that provide the relief patients so desperately need, while avoiding the debilitating addiction that often comes with the use of opioids. Roughly 80,000 Americans died in 2022 from the overuse of opioids and there is no doubt that a good number of those started their opioid use to reduce physical pain of various types.
Scilex recognizes this problem and is committed to developing and commercializing solutions. And this isn’t a clinical stage company, although Scilex has several exciting products in the development pipeline. Scilex currently has one major product on the market—ZTlido, which is a topical pain-relieving patch that has better adhesion and better proven pain reduction than comparable products. Sales of ZTlido are increasing as more doctors become aware of the product and its benefits.
The company isn’t just resting on the success that ZTlido is showing, but pushing to get more pain-relieving products into the market to help patients that need pain relief. One of the major characteristics of this company that we appreciate and believe adds to the value proposition in the infrastructure already in place for ZTlido that can easily accommodate future pain-relieving solutions. The company has a national sales force in place that will target many of the same doctors and distributors for all its products, meaning that won’t have to add substantially to labor costs with the launch of each new product into the market. Additionally, the company has its manufacturing facility with its partner in Japan in place already with ZTlido. And that facility has seen the potential for added demand from Scilex and added capacity to meet future demand. This ability to scale up production and marketing without adding to costs in a substantive way leads us to believe that SCLX is poised to move higher as margins and profitability grow.
The final thing we want to highlight is the management team guiding Scilex. We have long believed that management is crucial to company success, and even more so in the drug development industry due to the regulatory hurdles. At the top of this team are CEO Jaisim Shah and Executive Chairman Henry Ji. Between these two leaders, the company benefits from over 60 years of global biopharmaceutical and biotechnology experience, including stints at companies such as Bristol-Myers Squibb, Biogen and Pfizer, among others. We don’t believe that management means everything, but it often proves to be the difference between a financially successful company and one that isn’t.
We’ll summarize by urging investors to take a look at SCLX. A company that has a growing revenue stream and a growing portfolio of products that provide desperately needed relief to millions of patients, without the problems associated with opioids is one that we believe has solid current prospects and excellent future ones.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.
